239 related articles for article (PubMed ID: 16178783)
1. Thymidylate synthase structure, function and implication in drug discovery.
Costi MP; Ferrari S; Venturelli A; Calò S; Tondi D; Barlocco D
Curr Med Chem; 2005; 12(19):2241-58. PubMed ID: 16178783
[TBL] [Abstract][Full Text] [Related]
2. Folate-based thymidylate synthase inhibitors as anticancer drugs.
Jackman AL; Calvert AH
Ann Oncol; 1995 Nov; 6(9):871-81. PubMed ID: 8624289
[TBL] [Abstract][Full Text] [Related]
3. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer.
Van Triest B; Peters GJ
Oncology; 1999 Oct; 57(3):179-94. PubMed ID: 10545786
[TBL] [Abstract][Full Text] [Related]
6. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.
Van Triest B; Pinedo HM; Giaccone G; Peters GJ
Ann Oncol; 2000 Apr; 11(4):385-91. PubMed ID: 10847455
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability.
Kitchens ME; Forsthoefel AM; Barbour KW; Spencer HT; Berger FG
Mol Pharmacol; 1999 Nov; 56(5):1063-70. PubMed ID: 10531414
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition.
Bijnsdorp IV; Comijn EM; Padron JM; Gmeiner WH; Peters GJ
Oncol Rep; 2007 Jul; 18(1):287-91. PubMed ID: 17549381
[TBL] [Abstract][Full Text] [Related]
9. Novel chemical strategies for thymidylate synthase inhibition.
Gmeiner WH
Curr Med Chem; 2005; 12(2):191-202. PubMed ID: 15638735
[TBL] [Abstract][Full Text] [Related]
10. Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth.
Ferrari S; Severi L; Pozzi C; Quotadamo A; Ponterini G; Losi L; Marverti G; Costi MP
Vitam Horm; 2018; 107():473-513. PubMed ID: 29544641
[TBL] [Abstract][Full Text] [Related]
11. Folate-based thymidylate synthase inhibitors in cancer chemotherapy.
Takemura Y; Jackman AL
Anticancer Drugs; 1997 Jan; 8(1):3-16. PubMed ID: 9147608
[TBL] [Abstract][Full Text] [Related]
12. Future potential of thymidylate synthase inhibitors in cancer therapy.
Lehman NL
Expert Opin Investig Drugs; 2002 Dec; 11(12):1775-87. PubMed ID: 12457437
[TBL] [Abstract][Full Text] [Related]
13. Future challenges in the clinical development of thymidylate synthase inhibitor compounds.
Brandt DS; Chu E
Oncol Res; 1997; 9(8):403-10. PubMed ID: 9436193
[TBL] [Abstract][Full Text] [Related]
14. Thymidylate synthase inhibition: a structure-based rationale for drug design.
Costi MP
Med Res Rev; 1998 Jan; 18(1):21-42. PubMed ID: 9436180
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase inhibitors.
Touroutoglou N; Pazdur R
Clin Cancer Res; 1996 Feb; 2(2):227-43. PubMed ID: 9816165
[TBL] [Abstract][Full Text] [Related]
16. Kinetics and ligand-binding preferences of Mycobacterium tuberculosis thymidylate synthases, ThyA and ThyX.
Hunter JH; Gujjar R; Pang CK; Rathod PK
PLoS One; 2008 May; 3(5):e2237. PubMed ID: 18493582
[TBL] [Abstract][Full Text] [Related]
17. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
[TBL] [Abstract][Full Text] [Related]
18. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase.
Banerjee D; Mayer-Kuckuk P; Capiaux G; Budak-Alpdogan T; Gorlick R; Bertino JR
Biochim Biophys Acta; 2002 Jul; 1587(2-3):164-73. PubMed ID: 12084458
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase.
Jones TR; Varney MD; Webber SE; Lewis KK; Marzoni GP; Palmer CL; Kathardekar V; Welsh KM; Webber S; Matthews DA; Appelt K; Smith WW; Janson CA; Villafranca JE; Bacquet RJ; Howland EF; Booth CL; Herrmann SM; Ward RW; White J; Moomaw EW; Bartlett CA; Morse CA
J Med Chem; 1996 Feb; 39(4):904-17. PubMed ID: 8632414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]